TOP TIERMARKET NEWSWIRE
Movers explained · 2026-08-26

Archived explainer. For the current picture see today's SMMT page.

Why Is SUMMIT THERAPEUTICS (SMMT) Stock Up Today?

By the Top Tier Newswire AI Desk · August 26, 2026 at 9:34 AM ET · reviewed against 13 wire stories

SUMMIT THERAPEUTICS (SMMT) is up +9.66% in the latest session. Our newswire has captured 13 stories on SMMT across 7 sources in the last 36 hours, with AI sentiment reading bullish (avg 60/100).

Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.

Why SMMT stock is up today

Summit Therapeutics (SMMT) shares rose 9.66% to $14.65 in early trading on August 26, driven by positive developments from its partner Akeso regarding the Phase III HARMONi trial of ivonescimab. The trial showed a significant improvement in progression-free survival for patients with EGFR-mutated non-small cell lung cancer. The results were published and triggered a strong intraday response, including a 6.7% gap up from the prior close.

What Happened

Summit Therapeutics filed an 8-K with the SEC on August 26, disclosing other events and financial statements. The filing followed the announcement that ivonescimab, a lead asset licensed from Akeso, outperformed AstraZeneca’s Imfinzi in a late-stage trial. The drug combination extended progression-free survival in EGFR-mutated NSCLC patients, according to the HARMONi study results. This data was highlighted in multiple reports, including one from MarketChameleon and a Seeking Alpha analysis.

The news also led to a 7.75% rise in SMMT shares on the back of Akeso’s positive Phase III results for ivonescimab in advanced biliary tract cancer. Analysts at Guggenheim and H.C. Wainwright reiterated their existing ratings, with the latter maintaining a Neutral stance. The stock opened at $14.25 and reached a high of $15.68 before settling near $14.55.

What The Data Shows

The stock’s intraday performance showed a strong early reaction, with a high of $15.68 at 8:10 AM ET. Volume was 1.7 million shares, or 0.3 times the 3-month average. Recent insider transactions indicate confidence, with three executives buying shares totaling $103.6 million in the last 90 days. The stock has traded within a narrow range over the last eight sessions, moving just -0.1% from $13.24 to $13.23. On August 26, the stock printed two fresh 52-week highs and three 52-week lows.

What To Watch

Summit Therapeutics has no scheduled earnings report in the near term. Investors may want to monitor the breadth of analyst coverage and any further developments from the HARMONi trial or related partnerships.

AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.

SMMT by the numbers

Last: $14.65Session: +9.66%7 sessions: +10.95%Coverage: 13 stories / 7 sourcesAI sentiment: 60/100 (bullish)Mkt cap: $10.2B52w: $12.07 to $30.05
SMMT · Aug 26 session (5-min) · +6.94% vs prior close · updated 8:51 PM ET
$13.23$14.43$15.63prev close $13.36$14.297:00 AM10:13 AM1:27 PM4:41 PM7:55 PM7:00 AM · $14.447:05 AM · $14.597:10 AM · $14.567:15 AM · $14.497:20 AM · $14.417:25 AM · $14.477:30 AM · $14.467:35 AM · $14.557:40 AM · $14.577:45 AM · $14.687:50 AM · $14.717:55 AM · $14.948:00 AM · $14.998:05 AM · $15.508:10 AM · $15.408:15 AM · $15.098:20 AM · $15.328:25 AM · $15.308:30 AM · $15.388:35 AM · $15.268:40 AM · $15.358:45 AM · $15.358:50 AM · $15.288:55 AM · $15.259:00 AM · $15.099:05 AM · $15.069:10 AM · $15.069:15 AM · $14.789:20 AM · $14.709:25 AM · $14.709:30 AM · $14.569:35 AM · $14.419:40 AM · $14.669:45 AM · $14.839:50 AM · $14.859:55 AM · $14.9110:00 AM · $14.6410:05 AM · $14.6610:10 AM · $14.4310:15 AM · $14.4410:20 AM · $14.2810:25 AM · $14.1410:30 AM · $14.2610:35 AM · $14.1910:40 AM · $14.1910:45 AM · $14.2110:50 AM · $14.1610:55 AM · $14.2111:00 AM · $14.2111:05 AM · $14.1911:10 AM · $14.1611:15 AM · $14.1511:20 AM · $14.1611:25 AM · $14.2311:30 AM · $14.2411:35 AM · $14.2611:40 AM · $14.2611:45 AM · $14.2111:50 AM · $14.1711:55 AM · $14.2412:00 PM · $14.2812:05 PM · $14.3312:10 PM · $14.2712:15 PM · $14.2912:20 PM · $14.2812:25 PM · $14.2712:30 PM · $14.3712:35 PM · $14.4112:40 PM · $14.4112:45 PM · $14.3912:50 PM · $14.3612:55 PM · $14.361:00 PM · $14.411:05 PM · $14.411:10 PM · $14.381:15 PM · $14.371:20 PM · $14.421:25 PM · $14.401:30 PM · $14.421:35 PM · $14.431:40 PM · $14.491:45 PM · $14.451:50 PM · $14.451:55 PM · $14.592:00 PM · $14.642:05 PM · $14.532:10 PM · $14.462:15 PM · $14.462:20 PM · $14.482:25 PM · $14.442:30 PM · $14.392:35 PM · $14.352:40 PM · $14.342:45 PM · $14.352:50 PM · $14.352:55 PM · $14.343:00 PM · $14.373:05 PM · $14.353:10 PM · $14.343:15 PM · $14.393:20 PM · $14.353:25 PM · $14.373:30 PM · $14.363:35 PM · $14.393:40 PM · $14.383:45 PM · $14.353:50 PM · $14.273:55 PM · $14.214:00 PM · $14.204:10 PM · $14.224:20 PM · $14.204:25 PM · $14.204:35 PM · $14.234:45 PM · $14.264:55 PM · $14.315:15 PM · $14.275:25 PM · $14.285:30 PM · $14.205:35 PM · $14.255:45 PM · $14.205:50 PM · $14.205:55 PM · $14.306:00 PM · $14.316:05 PM · $14.226:10 PM · $14.306:20 PM · $14.266:25 PM · $14.226:35 PM · $14.226:45 PM · $14.227:10 PM · $14.307:30 PM · $14.307:40 PM · $14.257:45 PM · $14.257:50 PM · $14.277:55 PM · $14.29
AI sentiment, last 36h · averaged over 13 stories · 60/100 bullish
AI sentiment 60/100 (bullish)0 · bearish50bullish · 100

The headlines behind the move

Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
36h ago24h ago12h agopublishMarketChameleon · sentiment 73 · Ivonescimab Plus Chemotherapy Extends Progression-Free Survival in EGFR-Mutated NSCLC: Phase III HARMONi Study Results Published August 25, 2026MarketChameleon · 73Ivonescimab Plus Chemotherapy Extends Progression-Free Survival in EGFR-Mutated NSCLC: Ph…Investing.com Markets · sentiment 67 · Summit Therapeutics stock jumps on partner’s cancer trial dataInvesting.com Markets · 67Summit Therapeutics stock jumps on partner’s cancer trial dataInvesting.com Analyst Ratings · sentiment 50 · H.C. Wainwright reiterates Neutral stock rating on Summit TherapeuticsInvesting.com Analyst Ratings · 50H.C. Wainwright reiterates Neutral stock rating on Summit TherapeuticsInvesting.com Markets · sentiment 50 · Why is Summit Therapeutics stock surging today?Investing.com Markets · 50Why is Summit Therapeutics stock surging today?Seeking Alpha · sentiment 73 · Summit rises as lead drug from Akeso outperforms Astra’s Imfinzi in late-stage trialSeeking Alpha · 73Summit rises as lead drug from Akeso outperforms Astra’s Imfinzi in late-stage trialInvesting.com Analyst Ratings · sentiment 56 · Guggenheim reiterates Summit Therapeutics stock rating on trial dataInvesting.com Analyst Ratings · 56Guggenheim reiterates Summit Therapeutics stock rating on trial dataInvestorsHub · sentiment 69 · Summit Therapeutics shares rise after partner reports positive Phase III cancer trial resultsInvestorsHub · 69Summit Therapeutics shares rise after partner reports positive Phase III cancer trial res…SEC 8-K · sentiment 50 · Summit Therapeutics Inc. (SMMT) files 8-KSEC 8-K · 50Summit Therapeutics Inc. (SMMT) files 8-K
17d agoSEC 8-KNEUTRAL 50General

Summit Therapeutics Inc. (SMMT) files 8-K

Filed: 2026-08-26 AccNo: 0001599298-26-000074 Size: 1 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

17d agoInvestorsHubBULLISH 69Product/PR

Summit Therapeutics shares rise after partner reports positive Phase III cancer trial results

Summit Therapeutics shares rise 7.75% after partner Akeso reports positive Phase III results for ivonescimab in advanced biliary tract cancer.

18d agoInvesting.com Analyst RatingsBULLISH 56Analyst

Guggenheim reiterates Summit Therapeutics stock rating on trial data

Guggenheim reiterates Summit Therapeutics stock rating on trial data

18d agoSeeking AlphaBULLISH 73Product/PR

Summit rises as lead drug from Akeso outperforms Astra’s Imfinzi in late-stage trial

Summit Therapeutics (SMMT) stock jumps as lead asset, ivonescimab, licensed from Akeso (AKESF), outperforms AstraZeneca

18d agoInvesting.com MarketsNEUTRAL 50General

Why is Summit Therapeutics stock surging today?

Why is Summit Therapeutics stock surging today?

18d agoInvesting.com Analyst RatingsNEUTRAL 50Analyst

H.C. Wainwright reiterates Neutral stock rating on Summit Therapeutics

H.C. Wainwright reiterates Neutral stock rating on Summit Therapeutics

18d agoInvesting.com MarketsBULLISH 67Product/PR

Summit Therapeutics stock jumps on partner’s cancer trial data

Summit Therapeutics stock jumps on partner’s cancer trial data

19d agoMarketChameleonBULLISH 73Product/PR

Ivonescimab Plus Chemotherapy Extends Progression-Free Survival in EGFR-Mutated NSCLC: Phase III HARMONi Study Results Published August 25, 2026

Summit Therapeutics' global Phase III HARMONi trial demonstrates a significant and clinically meaningful increase in progression-free survival for EGFR-mutated NSCLC patients treated with ivonescimab plus chemotherapy after progression on EGFR TKI, according to a new publication in The Lancet Oncology. Upcoming key data presentations and regulatory dates could shape the therapy’s future prospects.

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on SMMT: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.

Earlier SMMT move explainers: 2026-09-04 · 2026-09-03 · 2026-09-01 · 2026-08-27 · 2026-08-26 · 2026-08-25 · 2026-08-17